bioRxiv Science⌕ Search

Biology subjects

Abu-Farha, M.

Publications and source records attributed to Abu-Farha, M..

2 recordsLinked to original sources

ANGPTL8 R59W variant influences inflammation through modulating NF-κB pathway under TNFα stimulation

BackgroundANGPTL8 is known to regulate lipid metabolism and inflammation. It interacts with ANGPTL3 and ANGPTL4 to regulate LPL activity, and with IKK/{beta} to modulate NF-{kappa}B activity. Further, a SNP leading to ANGPTL8 R59W variant associates with reduced LDL/HDL and increased FBG in Hispanic and Arab individuals, respectively. In this study, we investigate the impact of R59W variant on the inflammatory activity of ANGPTL8. MethodsANGPTL8 R59W variant was genotyped in a discovery cohort of 867 Arab individuals from Kuwait. Plasma levels of ANGPTL8 and inflammatory markers were measured and tested for associations with the genotype; the associations were tested for replication in an independent cohort of 278 Arab individuals. Impact of the ANGPTL8 R59W variant on NF-{kappa}B activity was examined using approaches including overexpression, luciferase assay, and structural modeling of binding dynamics. ResultsThe ANGPTL8 R59W variant was associated with increased circulatory levels of TNF and IL7. NF-{kappa}B activity, as assessed by the increased in the phosphorylation of IKK-/{beta} protein, I{kappa}B, and NF-{kappa}B p-65 in R59W variant compared to wild type, and TNF stimulation further elevated it. This finding was substantiated by increased luciferase activity of NF-{kappa}B p65 with the R59W variant. Modeled structural and binding variation due to R59W change in ANGPTL8 agreed with the observed increase in NF-{kappa}B activity. ConclusionANGPTL8 R59W is associated with increased circulatory TNF, IL7 and NF-{kappa}B p65 activity. Weak transient binding of ANGPTL8 R59W variant explains its regulatory role on the NF-{kappa}B pathway and inflammation.

biochemistry↗

A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine

The severity of the new COVID-19 pandemic caused by the SARS-CoV-2 virus is strikingly variable in different global populations. SARS-CoV-2 uses ACE2 as a cell receptor, TMPRSS2 protease, and FURIN peptidase to invade human cells. Here, we investigated 1,378 whole-exome sequences of individuals from the Middle Eastern populations (Kuwait, Qatar, and Iran) to explore natural variations in the ACE2, TMPRSS2, and FURIN genes. We identified two activating variants (K26R and N720D) in the ACE2 gene that are more common in Europeans than in the Middle Eastern, East Asian, and African populations. We postulate that K26R can activate ACE2 and facilitate binding to S-protein RBD while N720D enhances TMPRSS2 cutting and, ultimately, viral entry. We also detected deleterious variants in FURIN that are frequent in the Middle Eastern but not in the European populations. This study highlights specific genetic variations in the ACE2 and FURIN genes that may explain SARS-CoV-2 clinical disparity. We showed structural evidence of the functionality of these activating variants that increase the SARS-CoV-2 aggressiveness. Finally, our data illustrate a significant correlation between ACE2 variants identified in people from Middle Eastern origins that can be further explored to explain the variation in COVID-19 infection and mortality rates globally.

genetics↗